TABLE 3.
Antimicrobial activities of cefepime-taniborbactam and comparators tested against Pseudomonas spp. by species and major phenotypes
| Organisms (no. tested) and antimicrobial(s) | MIC (mg/L) |
% of isolates S, I, or R by: |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| EUCAST |
CLSI |
||||||||
| MIC50 | MIC90 | Range | S | I | R | S | I | R | |
| All Pseudomonas spp. (n = 170) | |||||||||
| Cefepime | 32 | >32 | 1 to >32 | 0.0 | 20.0 | 80.0 | 20.0 | 25.3 | 54.7 |
| Cefepime-taniborbactama | 8/4 | 32/4 | ≤0.06/4 to 32/4 | 67.6 | 32.4 | 67.6 | 32.4 | ||
| Piperacillin-tazobactam | 128/4 | >128/4 | 1/4 to >128/4 | 0 | 17.6 | 82.4 | 17.6 | 19.4 | 62.9 |
| Meropenem | 32 | 128 | ≤0.5 to >128 | 4.1 | 24.1 | 71.8 | 4.1 | 7.1 | 88.8 |
| Meropenem-vaborbactam | 32/8 | >32/8 | ≤0.06/8 to >32/8 | 32.9 | 67.1 | 14.7 | 2.4 | 67.1 | |
| Ceftolozane-tazobactam | 8/4 | >32/4 | ≤0.25/4 to >32/4 | 34.7 | 65.3 | 34.7 | 28.2 | 37.1 | |
| Ceftazidime-avibactam | 8/4 | >32/4 | ≤0.25/4 to >32/4 | 61.2 | 38.8 | 61.2 | 38.8 | ||
| Imipenem-relebactam | 16/4 | >32/4 | ≤0.12/4 to >32/4 | 37.1 | 62.9 | ||||
| Levofloxacin | >4 | >4 | ≤0.25 to >4 | 0.0 | 12.4 | 87.6 | 5.9 | 6.5 | 87.6 |
| Amikacin | 8 | 64 | ≤0.5 to >64 | 64.7 | 35.3 | 64.7 | 5.9 | 29.4 | |
| Tigecycline | >1 | >1 | 0.25 to >1 | 1.2 | 98.8 | ||||
| All P. aeruginosa (n = 163) | |||||||||
| Cefepime | 32 | >32 | 1 to >32 | 0 | 20.2 | 79.8 | 20.2 | 25.8 | 54.0 |
| Cefepime-taniborbactama | 8/4 | 32/4 | ≤0.06/4 to 32/4 | 67.5 | 32.5 | 67.5 | 32.5 | ||
| Piperacillin-tazobactam | 128/4 | >128/4 | 1/4 to >128/4 | 0.0 | 17.8 | 82.2 | 17.8 | 19.0 | 63.2 |
| Meropenem | 32 | 128 | ≤0.5 to >128 | 4.3 | 25.2 | 70.6 | 4.3 | 7.4 | 88.3 |
| Meropenem-vaborbactam | 32/8 | >32/8 | ≤0.06/8 to >32/8 | 33.7 | 66.3 | 15.3 | 1.8 | 66.3 | |
| Ceftolozane-tazobactam | 8/4 | >32/4 | ≤0.25/4 to >32/4 | 36.2 | 63.8 | 36.2 | 29.4 | 34.4 | |
| Ceftazidime-avibactam | 8/4 | >32/4 | ≤0.25/4 to >32/4 | 63.2 | 36.8 | 63.2 | 36.8 | ||
| Imipenem-relebactam | 8/4 | >32/4 | ≤0.12/4 to >32/4 | 38.7 | 61.3 | ||||
| Levofloxacin | >4 | >4 | ≤0.25 to >4 | 0 | 12.9 | 87.1 | 6.1 | 6.7 | 87.1 |
| Amikacin | 8 | 64 | ≤0.5 to >64 | 64.4 | 35.6 | 64.4 | 6.1 | 29.4 | |
| Tigecycline | 5 | 5 | 0.25 to >1 | 1.2 | 98.8 | ||||
| All other Pseudomonas spp. (n = 7) | |||||||||
| Cefepime | 4 to >32 | 0 | 14.3 | 85.7 | 14.3 | 14.3 | 71.4 | ||
| Cefepime-taniborbactama | 4/4 to >32/4 | 71.4 | 28.6 | 71.4 | 28.6 | ||||
| Piperacillin-tazobactam | 16/4 to >128/4 | 0 | 14.3 | 85.7 | 14.3 | 28.6 | 57.1 | ||
| Meropenem | 16 to >128 | 0 | 0 | 100 | 0 | 0 | 100 | ||
| Meropenem-varbobactam | 8/8 to >32/8 | 14.3 | 85.7 | 0 | 14.3 | 85.7 | |||
| Ceftolozane-tazobactam | 32/4 to >32/4 | 0 | 100.0 | 0 | 0 | 100 | |||
| Ceftazidime-avibactam | 8/4 to >32/4 | 14.3 | 85.7 | 14.3 | 85.7 | ||||
| Imipenem-relebactam | 32/4 to >32/4 | 0 | 100 | ||||||
| Levofloxacin | 2 to >4 | 0 | 0 | 100 | 0 | 0 | 100 | ||
| Amikacin | ≤0.5 to >32 | 71.4 | 28.6 | 71.4 | 28.6 | ||||
| Tigecycline | 1 to >1 | 0 | 100 | ||||||
a
Cefepime-taniborbactam provisional breakpoint: S, ≤8/4 mg/L; R, >8/4 mg/L.